5/2
08:08 am
mist
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 [Yahoo! Finance]
Low
Report
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 [Yahoo! Finance]
5/2
08:00 am
mist
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
Low
Report
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
4/17
08:10 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium [Yahoo! Finance]
Low
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium [Yahoo! Finance]
4/17
08:00 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
Low
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
4/8
11:45 am
mist
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting [Yahoo! Finance]
Low
Report
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting [Yahoo! Finance]
4/8
11:36 am
mist
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Low
Report
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
4/3
08:00 am
mist
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
Medium
Report
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
4/1
08:19 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences [Yahoo! Finance]
Medium
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences [Yahoo! Finance]
4/1
08:00 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
Medium
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
3/28
07:09 am
mist
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia [Yahoo! Finance]
3/28
07:00 am
mist
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Medium
Report
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
3/22
02:32 pm
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
3/21
07:28 am
mist
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]
3/21
07:14 am
mist
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
Medium
Report
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
3/5
09:11 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its price target lowered by analysts at Piper Sandler from $6.00 to $5.00. They now have an "overweight" rating on the stock.
Medium
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its price target lowered by analysts at Piper Sandler from $6.00 to $5.00. They now have an "overweight" rating on the stock.
2/29
04:13 pm
mist
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
Medium
Report
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
2/29
04:01 pm
mist
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
Medium
Report
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
2/29
07:23 am
mist
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants [Yahoo! Finance]
2/29
07:00 am
mist
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
Medium
Report
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
2/28
04:37 pm
mist
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
High
Report
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
2/26
12:16 pm
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
2/26
07:07 am
mist
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT [Yahoo! Finance]
High
Report
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT [Yahoo! Finance]
2/26
07:00 am
mist
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
High
Report
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT